BE2016C014I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C014I2
Authority: BE; Belgium

Application number

BE2016C014C

Other languages

French (fr)

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-15

Filing date

2016-04-21

Publication date

2024-10-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-04-21 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2024-10-09 Publication of BE2016C014I2 publication Critical patent/BE2016C014I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)

BE2016C014C 2004-04-15 2016-04-21 BE2016C014I2 (xx)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date
US56234004P	2004-04-15	2004-04-15
US56909604P	2004-05-07	2004-05-07
US59940104P	2004-08-06	2004-08-06
US61000104P	2004-09-14	2004-09-14
US61015904P	2004-09-14	2004-09-14
US61000204P	2004-09-14	2004-09-14
US62057304P	2004-10-20	2004-10-20

Publications (1)

Publication Number	Publication Date
BE2016C014I2 true BE2016C014I2 (xx)	2024-10-09

Family

ID=34965899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C014C BE2016C014I2 (xx)	2004-04-15	2016-04-21

Country Status (17)

Country	Link
US (9)	US8129346B2 (xx)
EP (1)	EP1745064B1 (xx)
JP (3)	JP5616569B2 (xx)
CN (2)	CN102174076A (xx)
AT (1)	ATE494298T1 (xx)
AU (1)	AU2005238445B2 (xx)
BE (1)	BE2016C014I2 (xx)
BR (1)	BRPI0509879A (xx)
CA (1)	CA2562411A1 (xx)
CY (1)	CY1117244T1 (xx)
DE (1)	DE602005025750D1 (xx)
DK (1)	DK1745064T3 (xx)
IL (3)	IL178400A (xx)
PL (1)	PL1745064T3 (xx)
PT (1)	PT1745064E (xx)
SG (2)	SG185306A1 (xx)
WO (1)	WO2005105827A2 (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012203602B2 (en) *	2004-04-15	2015-08-27	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
US7232818B2 (en)	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
WO2005105827A2 (en)	2004-04-15	2005-11-10	Proteolix, Inc.	Compounds for proteasome enzyme inhibition
US8198270B2 (en)	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
JP5108509B2 (ja)	2004-05-10	2012-12-26	プロテオリックス，インコーポレイテッド	酵素阻害のための化合物
KR101299821B1 (ko) *	2004-12-07	2013-09-03	프로테올릭스, 인코퍼레이티드	프로테아좀 저해를 위한 조성물
MX2008006090A (es)	2005-11-09	2008-10-23	Proteolix Inc	Compuestos para inhibicion de la enzima.
RU2450016C2 (ru)	2006-06-19	2012-05-10	Протеоликс, Инк.	Пептидные эпоксикетоны для ингибирования протеасомы
KR20160086980A (ko)	2007-10-04	2016-07-20	오닉스 세라퓨틱스, 인크.	결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
MX2011004225A (es)	2008-10-21	2011-06-21	Onyx Therapeutics Inc	Terapia de combinacion con epoxicetonas peptidicas.
PT2408802T (pt)	2009-03-16	2017-08-03	Governing Council Univ Toronto	Moléculas de aminoácido ciclicas e métodos para as preparar
AR075899A1 (es)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
GB0914883D0 (en)	2009-08-26	2009-09-30	Univ Belfast	Compound
WO2011060179A1 (en)	2009-11-13	2011-05-19	Onyx Therapeutics, Inc	Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt)	2010-03-01	2018-05-08	Onyx Therapeutics Inc	composto para a inibição de imunoproteassoma
EP2555621A4 (en)	2010-04-07	2014-07-02	Onyx Therapeutics Inc	CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
SMT202400264T1 (it)	2012-05-08	2024-07-09	Onyx Therapeutics Inc	Metodi di complessazione di ciclodestrina per formulare inibitori del proteasoma peptidico
WO2014011695A2 (en) *	2012-07-09	2014-01-16	Onyx Therapeutics, Inc.	Prodrugs of peptide epoxy ketone protease inhibitors
US10076384B2 (en)	2013-03-08	2018-09-18	Symple Surgical, Inc.	Balloon catheter apparatus with microwave emitter
PL2968555T3 (pl)	2013-03-13	2020-11-16	Sanofi	Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
MX372671B (es)	2013-07-19	2020-04-23	Onyx Therapeutics Inc	Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CN103360348B (zh) *	2013-07-25	2015-06-24	苏州鹏旭医药科技有限公司	一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
US20160215016A1 (en) *	2013-09-06	2016-07-28	Sandoz Ag	Synthesis of peptide epoxy ketones
CA2922210A1 (en) *	2013-09-06	2015-03-12	Sandoz Ag	Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
CN104710507B (zh) *	2013-12-11	2018-08-14	深圳翰宇药业股份有限公司	一种卡非佐米的制备方法
WO2015121769A1 (en)	2014-02-13	2015-08-20	Ranbaxy Laboratories Limited	Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
JP6608442B2 (ja) *	2014-07-14	2019-11-20	セントラックスインターナショナル，インコーポレイテッド	酵素阻害に用いられるエポキシケトン化合物
WO2016046843A1 (en)	2014-09-24	2016-03-31	Biophore India Pharmaceuticals Pvt. Ltd.	Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en)	2014-10-27	2016-05-06	Apicore Us Llc	Methods of making carfilzomib and intermediates thereof
EP3227312B1 (en)	2014-12-02	2019-05-29	Fresenius Kabi Oncology Limited	A process for purification of carfilzomib
US10301353B2 (en)	2014-12-31	2019-05-28	Dr. Reddy's Laboratories Limited	Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2016116882A2 (en) *	2015-01-23	2016-07-28	Leiutis Pharmaceuticals Pvt Ltd	Novel compositions of carfilzomib
US10544189B2 (en) *	2015-04-22	2020-01-28	Msn Laboratories Private Limited	Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016170489A1 (en)	2015-04-24	2016-10-27	Fresenius Kabi Oncology Ltd.	Pharmaceutical compositions of proteasome inhibitor
US10364269B2 (en)	2015-05-21	2019-07-30	Laurus Labs Limited	Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
EP3377471A4 (en)	2015-11-11	2019-11-20	Encycle Therapeutics, Inc.	FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES
EP3494126A1 (en)	2016-08-02	2019-06-12	Synthon BV	Process for making carfilzomib
EP3512835B1 (en)	2016-09-14	2021-06-09	Fresenius Kabi Oncology Limited	A process for purification of carfilzomib intermediate
EP3538542B1 (en)	2016-11-11	2021-08-04	Zealand Pharma A/S	Cyclic peptides multimers targeting alpha 4beta 7 integrin
EP3330260A1 (en)	2016-12-01	2018-06-06	Enantia, S.L.	Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
CN106946981B (zh) *	2017-03-08	2020-08-21	南京陵瑞医药科技有限公司	一种四肽环氧丙烷衍生物及其制备方法和用途
JP7274425B2 (ja)	2017-05-10	2023-05-16	ジーランドファーマアクティーゼルスカブ	α４β７インテグリンを標的とするホモデチック環状ペプチド
BR112020005079A2 (pt)	2017-09-14	2020-09-15	Glaxosmithkline Intellectual Property Development Limited	tratamento de combinação para câncer
CN113185575B (zh) *	2021-05-11	2022-07-12	四川大学	一种花生抗氧化多肽及其制备方法
US20250302954A1 (en)	2022-05-11	2025-10-02	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
EP4685151A1 (en)	2024-07-24	2026-01-28	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Proteasome inhibitor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH01136498A (ja)	1987-11-21	1989-05-29	Nec Corp	状態監視用情報伝送装置
US5135919A (en)	1988-01-19	1992-08-04	Children's Medical Center Corporation	Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en)	1989-04-23	1995-08-15	The Trustees Of The University Of Pennsylvania	Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en)	1989-08-04	1991-12-10	Bristol-Myers Company	Antibiotic BU-4061T
US4990448A (en)	1989-08-04	1991-02-05	Bristol-Myers Company	Bu-4061T
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IE910713A1 (en)	1990-03-05	1991-09-11	Cephalon Inc	Chymotrypsin-like proteases
US5340736A (en)	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en)	1993-01-04	1993-03-03	Wellcome Found	Endothelin converting enzyme inhibitors
US5693617A (en)	1994-03-15	1997-12-02	Proscript, Inc.	Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en)	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en)	1995-04-12	2002-01-01	President And Fellows Of Harvard College	Lactacystin analogs
AU4499697A (en)	1996-09-13	1998-04-02	New York University	Method for treating parasitic diseases with proteasome inhibitors
DE69709671T2 (de)	1996-10-18	2002-08-22	Vertex Pharmaceuticals Inc., Cambridge	Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
SI0932617T1 (en)	1996-10-18	2002-06-30	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP0944312B9 (en)	1996-12-13	2006-07-05	ZymoGenetics, Inc.	Compositions and methods for stimulating bone growth
US6046177A (en)	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en)	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2210769T3 (es)	1997-06-13	2004-07-01	Cydex Inc.	Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6099851A (en)	1998-06-02	2000-08-08	Weisman; Kenneth M.	Therapeutic uses of leuprolide acetate
US6462019B1 (en)	1998-07-10	2002-10-08	Osteoscreen, Inc.	Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en)	1998-07-10	2005-01-04	Osteoscreen Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en)	1998-07-10	2005-06-07	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
AU762373B2 (en)	1998-10-20	2003-06-26	Millennium Pharmaceuticals, Inc.	Method for monitoring proteasome inhibitor drug action
US6492333B1 (en)	1999-04-09	2002-12-10	Osteoscreen, Inc.	Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) *	1999-05-12	2004-12-14	Yale University	Enzyme inhibition
EP1716861A3 (en) *	1999-10-20	2007-08-29	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone and hair growth
DK1326632T3 (da)	2000-10-12	2007-01-15	Viromics Gmbh	Protease-inhibitorer til behandling af infektioner af hepatitisvirus
WO2003059898A2 (en)	2002-01-08	2003-07-24	Eisai Co. Ltd.	Eponemycin and epoxomicin analogs and uses thereof
AU2003220685A1 (en)	2002-04-09	2003-10-27	Greenville Hospital System	Metastasis modulating activity of highly sulfated oligosaccharides
US20030224469A1 (en)	2002-06-03	2003-12-04	Buchholz Tonia J.	Methods and kits for assays utilizing fluorescence polarization
WO2005105827A2 (en) *	2004-04-15	2005-11-10	Proteolix, Inc.	Compounds for proteasome enzyme inhibition
US8198270B2 (en)	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
US7232818B2 (en)	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
AU2005243140A1 (en)	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
JP5108509B2 (ja)	2004-05-10	2012-12-26	プロテオリックス，インコーポレイテッド	酵素阻害のための化合物
EP2100899A3 (en)	2004-10-20	2009-09-30	Proteolix, Inc.	Compounds for proteasome enzyme inhibition
KR101299821B1 (ko)	2004-12-07	2013-09-03	프로테올릭스, 인코퍼레이티드	프로테아좀 저해를 위한 조성물
WO2006099261A2 (en)	2005-03-11	2006-09-21	The University Of North Carolina At Chapel Hill	Potent and specific immunoproteasome inhibitors
MX2008006090A (es)	2005-11-09	2008-10-23	Proteolix Inc	Compuestos para inhibicion de la enzima.
AR057227A1 (es)	2005-12-09	2007-11-21	Centocor Inc	Metodo para usar antagonistas de il6 con inhibidores del proteasoma
DE102006026464A1 (de)	2006-06-01	2007-12-06	Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma	Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
RU2450016C2 (ru)	2006-06-19	2012-05-10	Протеоликс, Инк.	Пептидные эпоксикетоны для ингибирования протеасомы
JP4325683B2 (ja) *	2007-02-14	2009-09-02	セイコーエプソン株式会社	画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (en)	2007-05-10	2008-11-20	Proteolix, Inc.	Compounds for enzyme inhibition
KR20160086980A (ko)	2007-10-04	2016-07-20	오닉스 세라퓨틱스, 인크.	결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
MX2011004225A (es)	2008-10-21	2011-06-21	Onyx Therapeutics Inc	Terapia de combinacion con epoxicetonas peptidicas.

2005
- 2005-04-14 WO PCT/US2005/012740 patent/WO2005105827A2/en not_active Ceased
- 2005-04-14 CA CA002562411A patent/CA2562411A1/en not_active Abandoned
- 2005-04-14 DK DK05735686.7T patent/DK1745064T3/da active
- 2005-04-14 PT PT05735686T patent/PT1745064E/pt unknown
- 2005-04-14 DE DE602005025750T patent/DE602005025750D1/de not_active Expired - Lifetime
- 2005-04-14 PL PL05735686T patent/PL1745064T3/pl unknown
- 2005-04-14 CN CN201110037869XA patent/CN102174076A/zh active Pending
- 2005-04-14 EP EP05735686A patent/EP1745064B1/en not_active Expired - Lifetime
- 2005-04-14 CN CN201310512372.8A patent/CN103554222A/zh active Pending
- 2005-04-14 AT AT05735686T patent/ATE494298T1/de active
- 2005-04-14 JP JP2007508543A patent/JP5616569B2/ja not_active Expired - Lifetime
- 2005-04-14 AU AU2005238445A patent/AU2005238445B2/en not_active Expired
- 2005-04-14 SG SG2012076659A patent/SG185306A1/en unknown
- 2005-04-14 US US11/578,626 patent/US8129346B2/en active Active
- 2005-04-14 SG SG200902548-7A patent/SG152239A1/en unknown
- 2005-04-14 BR BRPI0509879-3A patent/BRPI0509879A/pt not_active Application Discontinuation
2006
- 2006-09-28 IL IL178400A patent/IL178400A/en active IP Right Grant
2011
- 2011-02-18 CY CY20111100205T patent/CY1117244T1/el unknown
- 2011-09-12 JP JP2011198810A patent/JP2012041346A/ja active Pending
- 2011-12-22 US US13/334,372 patent/US8324174B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,288 patent/US8207125B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,466 patent/US8207126B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,544 patent/US8207127B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,469 patent/US8207297B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,263 patent/US8207124B2/en not_active Expired - Lifetime
- 2011-12-26 IL IL217210A patent/IL217210A0/en unknown
- 2011-12-26 IL IL217211A patent/IL217211A0/en unknown
2012
- 2012-03-02 US US13/411,044 patent/US20120277146A1/en not_active Abandoned
2013
- 2013-03-12 US US13/797,740 patent/US20130324459A1/en not_active Abandoned
- 2013-08-05 JP JP2013162017A patent/JP2014012676A/ja active Pending
2016
- 2016-04-21 BE BE2016C014C patent/BE2016C014I2/fr unknown

Also Published As

Publication number	Publication date
US20080200398A1 (en)	2008-08-21
EP1745064A2 (en)	2007-01-24
JP2008501637A (ja)	2008-01-24
US8207126B2 (en)	2012-06-26
IL217210A0 (en)	2012-01-31
CA2562411A1 (en)	2005-11-10
IL178400A (en)	2012-02-29
IL217211A0 (en)	2012-01-31
US20120101048A1 (en)	2012-04-26
HK1097860A1 (en)	2007-07-06
US8207124B2 (en)	2012-06-26
DK1745064T3 (da)	2011-04-11
SG152239A1 (en)	2009-05-29
US8207125B2 (en)	2012-06-26
US20120094930A1 (en)	2012-04-19
AU2005238445B2 (en)	2012-05-03
ATE494298T1 (de)	2011-01-15
PL1745064T3 (pl)	2011-06-30
CN103554222A (zh)	2014-02-05
US20120101050A1 (en)	2012-04-26
EP1745064B1 (en)	2011-01-05
AU2005238445A1 (en)	2005-11-10
IL178400A0 (en)	2007-02-11
CY1117244T1 (el)	2017-04-05
US20120277146A1 (en)	2012-11-01
PT1745064E (pt)	2011-03-23
US8129346B2 (en)	2012-03-06
BRPI0509879A (pt)	2007-10-16
US20120094926A1 (en)	2012-04-19
WO2005105827A2 (en)	2005-11-10
DE602005025750D1 (de)	2011-02-17
US8207297B2 (en)	2012-06-26
US20130324459A1 (en)	2013-12-05
US8207127B2 (en)	2012-06-26
JP5616569B2 (ja)	2014-10-29
CN102174076A (zh)	2011-09-07
US8324174B2 (en)	2012-12-04
JP2012041346A (ja)	2012-03-01
JP2014012676A (ja)	2014-01-23
WO2005105827A3 (en)	2006-03-30
US20120094928A1 (en)	2012-04-19
US20120094929A1 (en)	2012-04-19
SG185306A1 (en)	2012-11-29

Publication	Publication Date	Title
BE2024C508I2 (xx)	2024-08-08
BE2023C542I2 (xx)	2025-02-07
BE2022C549I2 (xx)	2024-08-08
BE2021C001I2 (xx)	2025-02-11
BE2020C513I2 (xx)	2024-08-08
BE2020C517I2 (xx)	2024-08-08
BE2019C540I2 (xx)	2024-08-08
BE2019C523I2 (xx)	2025-02-10
BE2019C548I2 (xx)	2024-10-09
BE2019C506I2 (xx)	2025-04-23
BE2018C045I2 (xx)	2024-08-08
BE2017C063I2 (xx)	2025-02-07
BE2017C027I2 (xx)	2024-08-08
BE2017C023I2 (xx)	2024-08-08
BE2017C002I2 (xx)	2024-08-08
BE2016C067I2 (xx)	2024-08-08
BE2016C014I2 (xx)	2024-10-09
BE2015C041I2 (xx)	2024-10-08
BE2015C038I2 (xx)	2019-10-23
BE2015C014I2 (xx)	2024-08-08
BE2014C071I2 (xx)	2024-10-08
BE2015C015I2 (xx)	2025-04-29
BE2014C064I2 (xx)	2024-08-08
BE2014C063I2 (xx)	2024-08-08
BE2014C010I2 (xx)	2024-08-08